Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Catalyst Pharmaceuticals (CPRX) Accumulated Depreciation & Amortization (2016 - 2025)

Catalyst Pharmaceuticals' Accumulated Depreciation & Amortization history spans 14 years, with the latest figure at -$604000.0 for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 34.42% year-over-year to -$604000.0; the TTM value through Dec 2025 reached -$604000.0, up 34.42%, while the annual FY2025 figure was -$604000.0, 34.42% up from the prior year.
  • Accumulated Depreciation & Amortization reached -$604000.0 in Q4 2025 per CPRX's latest filing, up from -$644000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $133000.0 in Q4 2022 to a low of -$921000.0 in Q4 2024.
  • Average Accumulated Depreciation & Amortization over 5 years is -$576050.0, with a median of -$711500.0 recorded in 2022.
  • The largest YoY upside for Accumulated Depreciation & Amortization was 114.65% in 2022 against a maximum downside of 14340.0% in 2022.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at -$908000.0 in 2021, then soared by 114.65% to $133000.0 in 2022, then crashed by 627.07% to -$701000.0 in 2023, then tumbled by 31.38% to -$921000.0 in 2024, then soared by 34.42% to -$604000.0 in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Accumulated Depreciation & Amortization are -$604000.0 (Q4 2025), -$644000.0 (Q3 2025), and -$73000.0 (Q2 2025).